CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus
Development of type 2 diabetes mellitus (T2DM) is preceded by insulin resistance (IR), which may evolve to impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). IFG and IGT are considered as prediabetic states (PD). Prediabetes indicates the high risk for the future development of...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ciborowski, Michal [verfasserIn] |
|---|
| Format: |
Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Rechteinformationen: |
Nutzungsrecht: © 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim © COPYRIGHT 2015 Wiley Subscription Services, Inc. |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Electrophoresis - Weinheim : Wiley-VCH, 1980, 36(2015), 18, Seite 2286-2293 |
|---|---|
| Übergeordnetes Werk: |
volume:36 ; year:2015 ; number:18 ; pages:2286-2293 |
| Links: |
|---|
| DOI / URN: |
10.1002/elps.201500021 |
|---|
| Katalog-ID: |
OLC1958970484 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1958970484 | ||
| 003 | DE-627 | ||
| 005 | 20230511112950.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1002/elps.201500021 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1958970484 | ||
| 035 | |a (DE-599)GBVOLC1958970484 | ||
| 035 | |a (PRQ)g1573-dc12e0ced3769a65fbcece9b63370f779961bb4d78262617cc8dcaa0a82dee993 | ||
| 035 | |a (KEY)0204026320150000036001802286cemsbasedserumfingerprintingtotrackevolutionoftype | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 570 |q DNB |
| 082 | 0 | 4 | |a 570 |q AVZ |
| 084 | |a BIODIV |2 fid | ||
| 084 | |a 35.29 |2 bkl | ||
| 100 | 1 | |a Ciborowski, Michal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Development of type 2 diabetes mellitus (T2DM) is preceded by insulin resistance (IR), which may evolve to impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). IFG and IGT are considered as prediabetic states (PD). Prediabetes indicates the high risk for the future development of diabetes, it is estimated that up to 70% of prediabetics eventually develop T2DM. The risk of T2DM development is increased in overweight (OW) and obese (OB) people; however normal weight (NW) individuals also suffer from T2DM. The present study was designed to evaluate whether changes in polar metabolites induced by T2DM evolution are different between NW, overweight and obese individuals. CE‐MS serum fingerprinting was performed on 197 serum samples obtained from OW, OB, and NW humans whom were IR, prediabetics, diabetics or with normal glucose homeostasis. Metabolic changes evoked by the progression of T2DM differ between obese, overweight, and normal weight subjects. Based on obtained results several metabolites can be proposed as a promising target to track T2DM evolution; BCAA in OW and NW humans, lysine in OB, while acetylcarnitine and methionine independently on body mass index. Validation of obtained results on larger population is required. | ||
| 540 | |a Nutzungsrecht: © 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim | ||
| 540 | |a © COPYRIGHT 2015 Wiley Subscription Services, Inc. | ||
| 650 | 4 | |a CE‐MS | |
| 650 | 4 | |a Serum metabolic fingerprinting | |
| 650 | 4 | |a Obesity | |
| 650 | 4 | |a Type 2 diabetes mellitus | |
| 650 | 4 | |a Diabetics | |
| 650 | 4 | |a Prediabetic state | |
| 650 | 4 | |a Analysis | |
| 650 | 4 | |a Glucose | |
| 650 | 4 | |a Type 2 diabetes | |
| 650 | 4 | |a Metabolites | |
| 650 | 4 | |a Glucose metabolism | |
| 650 | 4 | |a Dextrose | |
| 650 | 4 | |a Insulin resistance | |
| 700 | 1 | |a Adamska, Edyta |4 oth | |
| 700 | 1 | |a Rusak, Magdalena |4 oth | |
| 700 | 1 | |a Godzien, Joanna |4 oth | |
| 700 | 1 | |a Wilk, Juliusz |4 oth | |
| 700 | 1 | |a Citko, Anna |4 oth | |
| 700 | 1 | |a Bauer, Witold |4 oth | |
| 700 | 1 | |a Gorska, Maria |4 oth | |
| 700 | 1 | |a Kretowski, Adam |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Electrophoresis |d Weinheim : Wiley-VCH, 1980 |g 36(2015), 18, Seite 2286-2293 |w (DE-627)130409952 |w (DE-600)619001-7 |w (DE-576)015913732 |x 0173-0835 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2015 |g number:18 |g pages:2286-2293 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1002/elps.201500021 |3 Volltext |
| 856 | 4 | 2 | |u http://onlinelibrary.wiley.com/doi/10.1002/elps.201500021/abstract |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-TEC | ||
| 912 | |a SSG-OLC-CHE | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_4012 | ||
| 936 | b | k | |a 35.29 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 36 |j 2015 |e 18 |h 2286-2293 | ||
| author_variant |
m c mc |
|---|---|
| matchkey_str |
article:01730835:2015----::esaesrmigrrnigorceouinfy |
| hierarchy_sort_str |
2015 |
| bklnumber |
35.29 |
| publishDate |
2015 |
| allfields |
10.1002/elps.201500021 doi PQ20160617 (DE-627)OLC1958970484 (DE-599)GBVOLC1958970484 (PRQ)g1573-dc12e0ced3769a65fbcece9b63370f779961bb4d78262617cc8dcaa0a82dee993 (KEY)0204026320150000036001802286cemsbasedserumfingerprintingtotrackevolutionoftype DE-627 ger DE-627 rakwb eng 540 570 DNB 570 AVZ BIODIV fid 35.29 bkl Ciborowski, Michal verfasserin aut CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus 2015 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier Development of type 2 diabetes mellitus (T2DM) is preceded by insulin resistance (IR), which may evolve to impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). IFG and IGT are considered as prediabetic states (PD). Prediabetes indicates the high risk for the future development of diabetes, it is estimated that up to 70% of prediabetics eventually develop T2DM. The risk of T2DM development is increased in overweight (OW) and obese (OB) people; however normal weight (NW) individuals also suffer from T2DM. The present study was designed to evaluate whether changes in polar metabolites induced by T2DM evolution are different between NW, overweight and obese individuals. CE‐MS serum fingerprinting was performed on 197 serum samples obtained from OW, OB, and NW humans whom were IR, prediabetics, diabetics or with normal glucose homeostasis. Metabolic changes evoked by the progression of T2DM differ between obese, overweight, and normal weight subjects. Based on obtained results several metabolites can be proposed as a promising target to track T2DM evolution; BCAA in OW and NW humans, lysine in OB, while acetylcarnitine and methionine independently on body mass index. Validation of obtained results on larger population is required. Nutzungsrecht: © 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim © COPYRIGHT 2015 Wiley Subscription Services, Inc. CE‐MS Serum metabolic fingerprinting Obesity Type 2 diabetes mellitus Diabetics Prediabetic state Analysis Glucose Type 2 diabetes Metabolites Glucose metabolism Dextrose Insulin resistance Adamska, Edyta oth Rusak, Magdalena oth Godzien, Joanna oth Wilk, Juliusz oth Citko, Anna oth Bauer, Witold oth Gorska, Maria oth Kretowski, Adam oth Enthalten in Electrophoresis Weinheim : Wiley-VCH, 1980 36(2015), 18, Seite 2286-2293 (DE-627)130409952 (DE-600)619001-7 (DE-576)015913732 0173-0835 nnns volume:36 year:2015 number:18 pages:2286-2293 http://dx.doi.org/10.1002/elps.201500021 Volltext http://onlinelibrary.wiley.com/doi/10.1002/elps.201500021/abstract GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-BIODIV SSG-OLC-TEC SSG-OLC-CHE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_70 GBV_ILN_267 GBV_ILN_2018 GBV_ILN_2219 GBV_ILN_4012 35.29 AVZ AR 36 2015 18 2286-2293 |
| spelling |
10.1002/elps.201500021 doi PQ20160617 (DE-627)OLC1958970484 (DE-599)GBVOLC1958970484 (PRQ)g1573-dc12e0ced3769a65fbcece9b63370f779961bb4d78262617cc8dcaa0a82dee993 (KEY)0204026320150000036001802286cemsbasedserumfingerprintingtotrackevolutionoftype DE-627 ger DE-627 rakwb eng 540 570 DNB 570 AVZ BIODIV fid 35.29 bkl Ciborowski, Michal verfasserin aut CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus 2015 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier Development of type 2 diabetes mellitus (T2DM) is preceded by insulin resistance (IR), which may evolve to impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). IFG and IGT are considered as prediabetic states (PD). Prediabetes indicates the high risk for the future development of diabetes, it is estimated that up to 70% of prediabetics eventually develop T2DM. The risk of T2DM development is increased in overweight (OW) and obese (OB) people; however normal weight (NW) individuals also suffer from T2DM. The present study was designed to evaluate whether changes in polar metabolites induced by T2DM evolution are different between NW, overweight and obese individuals. CE‐MS serum fingerprinting was performed on 197 serum samples obtained from OW, OB, and NW humans whom were IR, prediabetics, diabetics or with normal glucose homeostasis. Metabolic changes evoked by the progression of T2DM differ between obese, overweight, and normal weight subjects. Based on obtained results several metabolites can be proposed as a promising target to track T2DM evolution; BCAA in OW and NW humans, lysine in OB, while acetylcarnitine and methionine independently on body mass index. Validation of obtained results on larger population is required. Nutzungsrecht: © 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim © COPYRIGHT 2015 Wiley Subscription Services, Inc. CE‐MS Serum metabolic fingerprinting Obesity Type 2 diabetes mellitus Diabetics Prediabetic state Analysis Glucose Type 2 diabetes Metabolites Glucose metabolism Dextrose Insulin resistance Adamska, Edyta oth Rusak, Magdalena oth Godzien, Joanna oth Wilk, Juliusz oth Citko, Anna oth Bauer, Witold oth Gorska, Maria oth Kretowski, Adam oth Enthalten in Electrophoresis Weinheim : Wiley-VCH, 1980 36(2015), 18, Seite 2286-2293 (DE-627)130409952 (DE-600)619001-7 (DE-576)015913732 0173-0835 nnns volume:36 year:2015 number:18 pages:2286-2293 http://dx.doi.org/10.1002/elps.201500021 Volltext http://onlinelibrary.wiley.com/doi/10.1002/elps.201500021/abstract GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-BIODIV SSG-OLC-TEC SSG-OLC-CHE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_70 GBV_ILN_267 GBV_ILN_2018 GBV_ILN_2219 GBV_ILN_4012 35.29 AVZ AR 36 2015 18 2286-2293 |
| allfields_unstemmed |
10.1002/elps.201500021 doi PQ20160617 (DE-627)OLC1958970484 (DE-599)GBVOLC1958970484 (PRQ)g1573-dc12e0ced3769a65fbcece9b63370f779961bb4d78262617cc8dcaa0a82dee993 (KEY)0204026320150000036001802286cemsbasedserumfingerprintingtotrackevolutionoftype DE-627 ger DE-627 rakwb eng 540 570 DNB 570 AVZ BIODIV fid 35.29 bkl Ciborowski, Michal verfasserin aut CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus 2015 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier Development of type 2 diabetes mellitus (T2DM) is preceded by insulin resistance (IR), which may evolve to impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). IFG and IGT are considered as prediabetic states (PD). Prediabetes indicates the high risk for the future development of diabetes, it is estimated that up to 70% of prediabetics eventually develop T2DM. The risk of T2DM development is increased in overweight (OW) and obese (OB) people; however normal weight (NW) individuals also suffer from T2DM. The present study was designed to evaluate whether changes in polar metabolites induced by T2DM evolution are different between NW, overweight and obese individuals. CE‐MS serum fingerprinting was performed on 197 serum samples obtained from OW, OB, and NW humans whom were IR, prediabetics, diabetics or with normal glucose homeostasis. Metabolic changes evoked by the progression of T2DM differ between obese, overweight, and normal weight subjects. Based on obtained results several metabolites can be proposed as a promising target to track T2DM evolution; BCAA in OW and NW humans, lysine in OB, while acetylcarnitine and methionine independently on body mass index. Validation of obtained results on larger population is required. Nutzungsrecht: © 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim © COPYRIGHT 2015 Wiley Subscription Services, Inc. CE‐MS Serum metabolic fingerprinting Obesity Type 2 diabetes mellitus Diabetics Prediabetic state Analysis Glucose Type 2 diabetes Metabolites Glucose metabolism Dextrose Insulin resistance Adamska, Edyta oth Rusak, Magdalena oth Godzien, Joanna oth Wilk, Juliusz oth Citko, Anna oth Bauer, Witold oth Gorska, Maria oth Kretowski, Adam oth Enthalten in Electrophoresis Weinheim : Wiley-VCH, 1980 36(2015), 18, Seite 2286-2293 (DE-627)130409952 (DE-600)619001-7 (DE-576)015913732 0173-0835 nnns volume:36 year:2015 number:18 pages:2286-2293 http://dx.doi.org/10.1002/elps.201500021 Volltext http://onlinelibrary.wiley.com/doi/10.1002/elps.201500021/abstract GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-BIODIV SSG-OLC-TEC SSG-OLC-CHE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_70 GBV_ILN_267 GBV_ILN_2018 GBV_ILN_2219 GBV_ILN_4012 35.29 AVZ AR 36 2015 18 2286-2293 |
| allfieldsGer |
10.1002/elps.201500021 doi PQ20160617 (DE-627)OLC1958970484 (DE-599)GBVOLC1958970484 (PRQ)g1573-dc12e0ced3769a65fbcece9b63370f779961bb4d78262617cc8dcaa0a82dee993 (KEY)0204026320150000036001802286cemsbasedserumfingerprintingtotrackevolutionoftype DE-627 ger DE-627 rakwb eng 540 570 DNB 570 AVZ BIODIV fid 35.29 bkl Ciborowski, Michal verfasserin aut CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus 2015 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier Development of type 2 diabetes mellitus (T2DM) is preceded by insulin resistance (IR), which may evolve to impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). IFG and IGT are considered as prediabetic states (PD). Prediabetes indicates the high risk for the future development of diabetes, it is estimated that up to 70% of prediabetics eventually develop T2DM. The risk of T2DM development is increased in overweight (OW) and obese (OB) people; however normal weight (NW) individuals also suffer from T2DM. The present study was designed to evaluate whether changes in polar metabolites induced by T2DM evolution are different between NW, overweight and obese individuals. CE‐MS serum fingerprinting was performed on 197 serum samples obtained from OW, OB, and NW humans whom were IR, prediabetics, diabetics or with normal glucose homeostasis. Metabolic changes evoked by the progression of T2DM differ between obese, overweight, and normal weight subjects. Based on obtained results several metabolites can be proposed as a promising target to track T2DM evolution; BCAA in OW and NW humans, lysine in OB, while acetylcarnitine and methionine independently on body mass index. Validation of obtained results on larger population is required. Nutzungsrecht: © 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim © COPYRIGHT 2015 Wiley Subscription Services, Inc. CE‐MS Serum metabolic fingerprinting Obesity Type 2 diabetes mellitus Diabetics Prediabetic state Analysis Glucose Type 2 diabetes Metabolites Glucose metabolism Dextrose Insulin resistance Adamska, Edyta oth Rusak, Magdalena oth Godzien, Joanna oth Wilk, Juliusz oth Citko, Anna oth Bauer, Witold oth Gorska, Maria oth Kretowski, Adam oth Enthalten in Electrophoresis Weinheim : Wiley-VCH, 1980 36(2015), 18, Seite 2286-2293 (DE-627)130409952 (DE-600)619001-7 (DE-576)015913732 0173-0835 nnns volume:36 year:2015 number:18 pages:2286-2293 http://dx.doi.org/10.1002/elps.201500021 Volltext http://onlinelibrary.wiley.com/doi/10.1002/elps.201500021/abstract GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-BIODIV SSG-OLC-TEC SSG-OLC-CHE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_70 GBV_ILN_267 GBV_ILN_2018 GBV_ILN_2219 GBV_ILN_4012 35.29 AVZ AR 36 2015 18 2286-2293 |
| allfieldsSound |
10.1002/elps.201500021 doi PQ20160617 (DE-627)OLC1958970484 (DE-599)GBVOLC1958970484 (PRQ)g1573-dc12e0ced3769a65fbcece9b63370f779961bb4d78262617cc8dcaa0a82dee993 (KEY)0204026320150000036001802286cemsbasedserumfingerprintingtotrackevolutionoftype DE-627 ger DE-627 rakwb eng 540 570 DNB 570 AVZ BIODIV fid 35.29 bkl Ciborowski, Michal verfasserin aut CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus 2015 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier Development of type 2 diabetes mellitus (T2DM) is preceded by insulin resistance (IR), which may evolve to impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). IFG and IGT are considered as prediabetic states (PD). Prediabetes indicates the high risk for the future development of diabetes, it is estimated that up to 70% of prediabetics eventually develop T2DM. The risk of T2DM development is increased in overweight (OW) and obese (OB) people; however normal weight (NW) individuals also suffer from T2DM. The present study was designed to evaluate whether changes in polar metabolites induced by T2DM evolution are different between NW, overweight and obese individuals. CE‐MS serum fingerprinting was performed on 197 serum samples obtained from OW, OB, and NW humans whom were IR, prediabetics, diabetics or with normal glucose homeostasis. Metabolic changes evoked by the progression of T2DM differ between obese, overweight, and normal weight subjects. Based on obtained results several metabolites can be proposed as a promising target to track T2DM evolution; BCAA in OW and NW humans, lysine in OB, while acetylcarnitine and methionine independently on body mass index. Validation of obtained results on larger population is required. Nutzungsrecht: © 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim © COPYRIGHT 2015 Wiley Subscription Services, Inc. CE‐MS Serum metabolic fingerprinting Obesity Type 2 diabetes mellitus Diabetics Prediabetic state Analysis Glucose Type 2 diabetes Metabolites Glucose metabolism Dextrose Insulin resistance Adamska, Edyta oth Rusak, Magdalena oth Godzien, Joanna oth Wilk, Juliusz oth Citko, Anna oth Bauer, Witold oth Gorska, Maria oth Kretowski, Adam oth Enthalten in Electrophoresis Weinheim : Wiley-VCH, 1980 36(2015), 18, Seite 2286-2293 (DE-627)130409952 (DE-600)619001-7 (DE-576)015913732 0173-0835 nnns volume:36 year:2015 number:18 pages:2286-2293 http://dx.doi.org/10.1002/elps.201500021 Volltext http://onlinelibrary.wiley.com/doi/10.1002/elps.201500021/abstract GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-BIODIV SSG-OLC-TEC SSG-OLC-CHE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_70 GBV_ILN_267 GBV_ILN_2018 GBV_ILN_2219 GBV_ILN_4012 35.29 AVZ AR 36 2015 18 2286-2293 |
| language |
English |
| source |
Enthalten in Electrophoresis 36(2015), 18, Seite 2286-2293 volume:36 year:2015 number:18 pages:2286-2293 |
| sourceStr |
Enthalten in Electrophoresis 36(2015), 18, Seite 2286-2293 volume:36 year:2015 number:18 pages:2286-2293 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
CE‐MS Serum metabolic fingerprinting Obesity Type 2 diabetes mellitus Diabetics Prediabetic state Analysis Glucose Type 2 diabetes Metabolites Glucose metabolism Dextrose Insulin resistance |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
Electrophoresis |
| authorswithroles_txt_mv |
Ciborowski, Michal @@aut@@ Adamska, Edyta @@oth@@ Rusak, Magdalena @@oth@@ Godzien, Joanna @@oth@@ Wilk, Juliusz @@oth@@ Citko, Anna @@oth@@ Bauer, Witold @@oth@@ Gorska, Maria @@oth@@ Kretowski, Adam @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
130409952 |
| dewey-sort |
3540 |
| id |
OLC1958970484 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">OLC1958970484</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230511112950.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">160206s2015 xx ||||| 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/elps.201500021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">PQ20160617</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC1958970484</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBVOLC1958970484</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PRQ)g1573-dc12e0ced3769a65fbcece9b63370f779961bb4d78262617cc8dcaa0a82dee993</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(KEY)0204026320150000036001802286cemsbasedserumfingerprintingtotrackevolutionoftype</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">570</subfield><subfield code="q">DNB</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">AVZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.29</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ciborowski, Michal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Development of type 2 diabetes mellitus (T2DM) is preceded by insulin resistance (IR), which may evolve to impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). IFG and IGT are considered as prediabetic states (PD). Prediabetes indicates the high risk for the future development of diabetes, it is estimated that up to 70% of prediabetics eventually develop T2DM. The risk of T2DM development is increased in overweight (OW) and obese (OB) people; however normal weight (NW) individuals also suffer from T2DM. The present study was designed to evaluate whether changes in polar metabolites induced by T2DM evolution are different between NW, overweight and obese individuals. CE‐MS serum fingerprinting was performed on 197 serum samples obtained from OW, OB, and NW humans whom were IR, prediabetics, diabetics or with normal glucose homeostasis. Metabolic changes evoked by the progression of T2DM differ between obese, overweight, and normal weight subjects. Based on obtained results several metabolites can be proposed as a promising target to track T2DM evolution; BCAA in OW and NW humans, lysine in OB, while acetylcarnitine and methionine independently on body mass index. Validation of obtained results on larger population is required.</subfield></datafield><datafield tag="540" ind1=" " ind2=" "><subfield code="a">Nutzungsrecht: © 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</subfield></datafield><datafield tag="540" ind1=" " ind2=" "><subfield code="a">© COPYRIGHT 2015 Wiley Subscription Services, Inc.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CE‐MS</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Serum metabolic fingerprinting</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Obesity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Type 2 diabetes mellitus</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diabetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prediabetic state</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Glucose</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Type 2 diabetes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metabolites</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Glucose metabolism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dextrose</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Insulin resistance</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Adamska, Edyta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rusak, Magdalena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Godzien, Joanna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilk, Juliusz</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Citko, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bauer, Witold</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gorska, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kretowski, Adam</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Electrophoresis</subfield><subfield code="d">Weinheim : Wiley-VCH, 1980</subfield><subfield code="g">36(2015), 18, Seite 2286-2293</subfield><subfield code="w">(DE-627)130409952</subfield><subfield code="w">(DE-600)619001-7</subfield><subfield code="w">(DE-576)015913732</subfield><subfield code="x">0173-0835</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:36</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:18</subfield><subfield code="g">pages:2286-2293</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://dx.doi.org/10.1002/elps.201500021</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">http://onlinelibrary.wiley.com/doi/10.1002/elps.201500021/abstract</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-TEC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-CHE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2219</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.29</subfield><subfield code="q">AVZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">36</subfield><subfield code="j">2015</subfield><subfield code="e">18</subfield><subfield code="h">2286-2293</subfield></datafield></record></collection>
|
| author |
Ciborowski, Michal |
| spellingShingle |
Ciborowski, Michal ddc 540 ddc 570 fid BIODIV bkl 35.29 misc CE‐MS misc Serum metabolic fingerprinting misc Obesity misc Type 2 diabetes mellitus misc Diabetics misc Prediabetic state misc Analysis misc Glucose misc Type 2 diabetes misc Metabolites misc Glucose metabolism misc Dextrose misc Insulin resistance CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus |
| authorStr |
Ciborowski, Michal |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)130409952 |
| format |
Article |
| dewey-ones |
540 - Chemistry & allied sciences 570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
OLC |
| remote_str |
false |
| illustrated |
Not Illustrated |
| issn |
0173-0835 |
| topic_title |
540 570 DNB 570 AVZ BIODIV fid 35.29 bkl CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus CE‐MS Serum metabolic fingerprinting Obesity Type 2 diabetes mellitus Diabetics Prediabetic state Analysis Glucose Type 2 diabetes Metabolites Glucose metabolism Dextrose Insulin resistance |
| topic |
ddc 540 ddc 570 fid BIODIV bkl 35.29 misc CE‐MS misc Serum metabolic fingerprinting misc Obesity misc Type 2 diabetes mellitus misc Diabetics misc Prediabetic state misc Analysis misc Glucose misc Type 2 diabetes misc Metabolites misc Glucose metabolism misc Dextrose misc Insulin resistance |
| topic_unstemmed |
ddc 540 ddc 570 fid BIODIV bkl 35.29 misc CE‐MS misc Serum metabolic fingerprinting misc Obesity misc Type 2 diabetes mellitus misc Diabetics misc Prediabetic state misc Analysis misc Glucose misc Type 2 diabetes misc Metabolites misc Glucose metabolism misc Dextrose misc Insulin resistance |
| topic_browse |
ddc 540 ddc 570 fid BIODIV bkl 35.29 misc CE‐MS misc Serum metabolic fingerprinting misc Obesity misc Type 2 diabetes mellitus misc Diabetics misc Prediabetic state misc Analysis misc Glucose misc Type 2 diabetes misc Metabolites misc Glucose metabolism misc Dextrose misc Insulin resistance |
| format_facet |
Aufsätze Gedruckte Aufsätze |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
nc |
| author2_variant |
e a ea m r mr j g jg j w jw a c ac w b wb m g mg a k ak |
| hierarchy_parent_title |
Electrophoresis |
| hierarchy_parent_id |
130409952 |
| dewey-tens |
540 - Chemistry 570 - Life sciences; biology |
| hierarchy_top_title |
Electrophoresis |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)130409952 (DE-600)619001-7 (DE-576)015913732 |
| title |
CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus |
| ctrlnum |
(DE-627)OLC1958970484 (DE-599)GBVOLC1958970484 (PRQ)g1573-dc12e0ced3769a65fbcece9b63370f779961bb4d78262617cc8dcaa0a82dee993 (KEY)0204026320150000036001802286cemsbasedserumfingerprintingtotrackevolutionoftype |
| title_full |
CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus |
| author_sort |
Ciborowski, Michal |
| journal |
Electrophoresis |
| journalStr |
Electrophoresis |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
txt |
| container_start_page |
2286 |
| author_browse |
Ciborowski, Michal |
| container_volume |
36 |
| class |
540 570 DNB 570 AVZ BIODIV fid 35.29 bkl |
| format_se |
Aufsätze |
| author-letter |
Ciborowski, Michal |
| doi_str_mv |
10.1002/elps.201500021 |
| dewey-full |
540 570 |
| title_sort |
ce‐ms‐based serum fingerprinting to track evolution of type 2 diabetes mellitus |
| title_auth |
CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus |
| abstract |
Development of type 2 diabetes mellitus (T2DM) is preceded by insulin resistance (IR), which may evolve to impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). IFG and IGT are considered as prediabetic states (PD). Prediabetes indicates the high risk for the future development of diabetes, it is estimated that up to 70% of prediabetics eventually develop T2DM. The risk of T2DM development is increased in overweight (OW) and obese (OB) people; however normal weight (NW) individuals also suffer from T2DM. The present study was designed to evaluate whether changes in polar metabolites induced by T2DM evolution are different between NW, overweight and obese individuals. CE‐MS serum fingerprinting was performed on 197 serum samples obtained from OW, OB, and NW humans whom were IR, prediabetics, diabetics or with normal glucose homeostasis. Metabolic changes evoked by the progression of T2DM differ between obese, overweight, and normal weight subjects. Based on obtained results several metabolites can be proposed as a promising target to track T2DM evolution; BCAA in OW and NW humans, lysine in OB, while acetylcarnitine and methionine independently on body mass index. Validation of obtained results on larger population is required. |
| abstractGer |
Development of type 2 diabetes mellitus (T2DM) is preceded by insulin resistance (IR), which may evolve to impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). IFG and IGT are considered as prediabetic states (PD). Prediabetes indicates the high risk for the future development of diabetes, it is estimated that up to 70% of prediabetics eventually develop T2DM. The risk of T2DM development is increased in overweight (OW) and obese (OB) people; however normal weight (NW) individuals also suffer from T2DM. The present study was designed to evaluate whether changes in polar metabolites induced by T2DM evolution are different between NW, overweight and obese individuals. CE‐MS serum fingerprinting was performed on 197 serum samples obtained from OW, OB, and NW humans whom were IR, prediabetics, diabetics or with normal glucose homeostasis. Metabolic changes evoked by the progression of T2DM differ between obese, overweight, and normal weight subjects. Based on obtained results several metabolites can be proposed as a promising target to track T2DM evolution; BCAA in OW and NW humans, lysine in OB, while acetylcarnitine and methionine independently on body mass index. Validation of obtained results on larger population is required. |
| abstract_unstemmed |
Development of type 2 diabetes mellitus (T2DM) is preceded by insulin resistance (IR), which may evolve to impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). IFG and IGT are considered as prediabetic states (PD). Prediabetes indicates the high risk for the future development of diabetes, it is estimated that up to 70% of prediabetics eventually develop T2DM. The risk of T2DM development is increased in overweight (OW) and obese (OB) people; however normal weight (NW) individuals also suffer from T2DM. The present study was designed to evaluate whether changes in polar metabolites induced by T2DM evolution are different between NW, overweight and obese individuals. CE‐MS serum fingerprinting was performed on 197 serum samples obtained from OW, OB, and NW humans whom were IR, prediabetics, diabetics or with normal glucose homeostasis. Metabolic changes evoked by the progression of T2DM differ between obese, overweight, and normal weight subjects. Based on obtained results several metabolites can be proposed as a promising target to track T2DM evolution; BCAA in OW and NW humans, lysine in OB, while acetylcarnitine and methionine independently on body mass index. Validation of obtained results on larger population is required. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-BIODIV SSG-OLC-TEC SSG-OLC-CHE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_70 GBV_ILN_267 GBV_ILN_2018 GBV_ILN_2219 GBV_ILN_4012 |
| container_issue |
18 |
| title_short |
CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus |
| url |
http://dx.doi.org/10.1002/elps.201500021 http://onlinelibrary.wiley.com/doi/10.1002/elps.201500021/abstract |
| remote_bool |
false |
| author2 |
Adamska, Edyta Rusak, Magdalena Godzien, Joanna Wilk, Juliusz Citko, Anna Bauer, Witold Gorska, Maria Kretowski, Adam |
| author2Str |
Adamska, Edyta Rusak, Magdalena Godzien, Joanna Wilk, Juliusz Citko, Anna Bauer, Witold Gorska, Maria Kretowski, Adam |
| ppnlink |
130409952 |
| mediatype_str_mv |
n |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1002/elps.201500021 |
| up_date |
2024-07-03T15:17:04.016Z |
| _version_ |
1803571506995789824 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">OLC1958970484</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230511112950.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">160206s2015 xx ||||| 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/elps.201500021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">PQ20160617</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC1958970484</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBVOLC1958970484</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PRQ)g1573-dc12e0ced3769a65fbcece9b63370f779961bb4d78262617cc8dcaa0a82dee993</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(KEY)0204026320150000036001802286cemsbasedserumfingerprintingtotrackevolutionoftype</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">570</subfield><subfield code="q">DNB</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">AVZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.29</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ciborowski, Michal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CE‐MS‐based serum fingerprinting to track evolution of type 2 diabetes mellitus</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Development of type 2 diabetes mellitus (T2DM) is preceded by insulin resistance (IR), which may evolve to impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). IFG and IGT are considered as prediabetic states (PD). Prediabetes indicates the high risk for the future development of diabetes, it is estimated that up to 70% of prediabetics eventually develop T2DM. The risk of T2DM development is increased in overweight (OW) and obese (OB) people; however normal weight (NW) individuals also suffer from T2DM. The present study was designed to evaluate whether changes in polar metabolites induced by T2DM evolution are different between NW, overweight and obese individuals. CE‐MS serum fingerprinting was performed on 197 serum samples obtained from OW, OB, and NW humans whom were IR, prediabetics, diabetics or with normal glucose homeostasis. Metabolic changes evoked by the progression of T2DM differ between obese, overweight, and normal weight subjects. Based on obtained results several metabolites can be proposed as a promising target to track T2DM evolution; BCAA in OW and NW humans, lysine in OB, while acetylcarnitine and methionine independently on body mass index. Validation of obtained results on larger population is required.</subfield></datafield><datafield tag="540" ind1=" " ind2=" "><subfield code="a">Nutzungsrecht: © 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</subfield></datafield><datafield tag="540" ind1=" " ind2=" "><subfield code="a">© COPYRIGHT 2015 Wiley Subscription Services, Inc.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CE‐MS</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Serum metabolic fingerprinting</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Obesity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Type 2 diabetes mellitus</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diabetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prediabetic state</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Glucose</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Type 2 diabetes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metabolites</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Glucose metabolism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dextrose</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Insulin resistance</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Adamska, Edyta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rusak, Magdalena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Godzien, Joanna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilk, Juliusz</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Citko, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bauer, Witold</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gorska, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kretowski, Adam</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Electrophoresis</subfield><subfield code="d">Weinheim : Wiley-VCH, 1980</subfield><subfield code="g">36(2015), 18, Seite 2286-2293</subfield><subfield code="w">(DE-627)130409952</subfield><subfield code="w">(DE-600)619001-7</subfield><subfield code="w">(DE-576)015913732</subfield><subfield code="x">0173-0835</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:36</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:18</subfield><subfield code="g">pages:2286-2293</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://dx.doi.org/10.1002/elps.201500021</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">http://onlinelibrary.wiley.com/doi/10.1002/elps.201500021/abstract</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-TEC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-CHE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2219</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.29</subfield><subfield code="q">AVZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">36</subfield><subfield code="j">2015</subfield><subfield code="e">18</subfield><subfield code="h">2286-2293</subfield></datafield></record></collection>
|
| score |
7.397667 |